BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. successfully finalized the fourth tranche of its private placement, raising $150,000 through the sale of 3 million units to support working capital and advance its acquired DPX™ immune education platform technology assets. The proceeds will enable the biopharmaceutical company to further its innovative immunotherapies for cancer, infectious diseases, and other immunological areas.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
